drugset / Trial / NCT02496078
A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether a regimen consisting of daclatasvir and asunaprevir is effective in treatment-naive patients with chronic hepatitis genotype 1b infection.
Timeline
- Start
- 2015-08
- Primary completion
- 2016-08
- Completion
- 2017-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Asunaprevir | Small molecule | 100 mg | — |
| Comparator | Daclatasvir | Small molecule | 60 mg | — |